VPC
BNTX icon

Vestal Point Capital’s BioNTech BNTX Stock Holding History

Vestal Point Capital’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$8.04M – 73
2024
Q2 		$8.04M Buy
+100,000
New +$9.14M 0.6% 36

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vestal Point Capital's BNTX Position: Q3 2024 in Review

Vestal Point Capital sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 100,000 shares — an estimated $8.04M sold.

Vestal Point Capital first reported a position in BNTX in Q2 2024 and held it in 1 quarter. The position peaked at $8.04M in Q2 2024. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

  • Vestal Point Capital reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
  • Vestal Point Capital sold 100,000 BioNTech shares in Q3 2024, an estimated $8.04M.
  • Vestal Point Capital first reported a position in BioNTech in Q2 2024 and held it in 1 quarter.
  • Vestal Point Capital's BioNTech position peaked at $8.04M in Q2 2024.
  • 296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.